Skip to content

Obesity Queue Database

Obesity Queue Database

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06391320
Enrollment
5000
Registered
2024-04-30
Start date
2023-09-01
Completion date
2028-12-31
Last updated
2024-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

To establish an obesity specific disease cohort database and form a special disease cohort, so as to provide guarantee for carrying out high-quality real-world clinical research and clinical research.

Interventions

OTHERother

Observational studies do not involve intervention

Sponsors

RenJi Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients aged 18-75 years with simple obesity. Simple obesity diagnosis criteria: meet one of the following conditions 1. BMI≥25 kg/m2 2. Waist circumference for male/female ≥90/80 cm 3. Waist-to-hip ratio: 0.9 (male); 0.85 (female)

Exclusion criteria

* Patients aged 18-75 years with simple obesity. Simple obesity diagnosis criteria: meet one of the following conditions 1. BMI≥25 kg/m2 2. Waist circumference for male/female ≥90/80 cm 3. Waist-to-hip ratio: 0.9 (male); 0.85 (female)

Design outcomes

Primary

MeasureTime frameDescription
MRI-PDFF intraperitoneal fat content, fasting and postprandial blood glucose, insulin, C-peptide, glycated hemoglobin, body weight, waist circumference, hip circumference5 yearsFor a specialized outpatient clinic for obesity, follow-ups should be conducted at 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years. During the trial period and the post-trial observation period, relevant safety indicators must be documented, analyzed statistically, and reported.

Secondary

MeasureTime frameDescription
Intestinal flora components, glucagon, gastrointestinal hormones GLP-1 and GIP, inflammatory immune indicators, etc5 yearsFor a specialized outpatient clinic for obesity, follow-ups should be conducted at 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years. During the trial period and the post-trial observation period, relevant safety indicators must be documented, analyzed statistically, and reported.

Countries

China

Contacts

Primary ContactJing Ma
cherry1996@live.cn+86 158 0098 3436

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026